Volume | 235,236 |
|
|||||
News | - | ||||||
Day High | 1.72 | Low High |
|||||
Day Low | 1.65 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Checkpoint Therapeutics Inc | CKPT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.69 | 1.65 | 1.72 | 1.69 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,360 | 235,236 | $ 1.68 | $ 395,600 | - | 1.30 - 3.62 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:20:26 | 2 | $ 1.665 | USD |
Checkpoint Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
39.29M | 23.53M | - | 103k | -51.85M | -2.20 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Checkpoint Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CKPT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.80 | 1.86 | 1.65 | 1.75 | 375,142 | -0.1303 | -7.24% |
1 Month | 1.87 | 2.15 | 1.65 | 1.89 | 356,613 | -0.2003 | -10.71% |
3 Months | 1.75 | 2.355 | 1.65 | 1.96 | 479,820 | -0.0803 | -4.59% |
6 Months | 1.98 | 3.62 | 1.36 | 2.14 | 651,595 | -0.3103 | -15.67% |
1 Year | 2.61 | 3.62 | 1.30 | 2.22 | 450,878 | -0.9403 | -36.03% |
3 Years | 28.10 | 46.40 | 1.30 | 18.44 | 649,654 | -26.43 | -94.06% |
5 Years | 28.80 | 53.762 | 1.30 | 22.31 | 608,128 | -27.13 | -94.20% |
Checkpoint Therapeutics Description
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). |